Coriell Institute for Medical Research

Precision health leader adds Coriell’s pharmacogenomics capabilities to expand the application of genomics and increase patient access to more personalized and effective health careST. PETERSBURG, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- InformedDNA®, a precision health company revolutionizing the application of genomic insights, today announced the acquisition of Coriell Life Sciences, a provider of pharmacogenomic services and clinical decision support. The addition of Coriell Life Science’s services to InformedDNA’s genetic test interpretation and counseling capabilities dramatically expands patient, provider and payor access to a broader range of genetic insights and enables more personalized, data-driven treatment and medication decisions for better outcomes and reduced healthcare costs. Philadelphia-based Coriell Life Sciences combines pharmacogenomics (the study of how genes affect an individual’s response to medication) and precision medicine (tailored diagnosis and treatment plans specific to each patient) to help large employers, health plans, payer organizations, health systems, and research institutions deliver paths to better health and more efficient care. The company’s offerings include both products and services. Corigen® is a population-scale medication risk management program that helps health plans, public and private employers, health systems, and pharmacy benefits managers ensure patients are getting the right medications for the best outcomes. Coriell Life Sciences also provides expert pharmacogenomic research analysis for laboratories. InformedDNA and Coriell Life Sciences have already started working together by integrating Coriell’s pharmacogenomic services into DNAimpact™, InformedDNA’s precision health platform. The combined offering identifies more targeted and effective therapies based on genomic profiles. It also combines interactive education and access to clinical experts to ensure patients and their providers are supported and guided to personalized health choices based on their genetics. Coriell Life Sciences CEO Scott Megill, who co-founded the company as a spin out from the Coriell Institute for Medical Research in 2013, will take on the new role of Chief Commercial Officer for InformedDNA. “The combination of our companies is a transformative step forward in the future of precision medicine,” said Megill. “By uniting our expertise in pharmacogenomics and clinical decision support with InformedDNA’s industry-leading genetic test interpretation and counseling services, we are creating an unparalleled resource for patients, providers, and health organizations. Already, through our new DNAimpact platform, we are expanding access to a broader range of genetic insights and helping individuals and healthcare teams make more personalized, data-driven decisions. This partnership ensures that more people than ever before can benefit from the life-changing potential of genetics.” “Pharmacogenomics is a critical aspect of personalized precision healthcare, and it presents an important opportunity to expand our ability to drive better patient outcomes,” said Dr. Surya Singh, CEO of InformedDNA. “Looking across the pharmacogenomics space, Coriell Life Sciences stands out for its extensive collaboration with leading laboratories that specialize in genetic and complex molecular testing. It also has experience working with a broad selection of employer plan sponsors. Scott and his team bring substantial expertise in the field and provide InformedDNA with an immediate presence in public employer plans currently underserved by precision medicine.” About Coriell Life SciencesCoriell Life Sciences (CLS), a leader in genetic science, uses innovation in precision medicine to reduce healthcare costs and empower a healthier world. With scientific expertise that spans six decades, CLS bridges the gap between genetic knowledge and clinical application and offers the most comprehensive medication risk management program on the market. For more information, visit https://www.coriell.com/. About InformedDNAInformedDNA® is the country's leading applied genomics solutions company, helping harness the full power of precision medicine. With the largest independent staff of board-certified genetics specialists in the U.S., InformedDNA ensures that health organizations have access to the highest quality, most current genomics insights to optimize clinical decisions. Founded to bring convenient telegenetic counseling to patients in all 50 states, InformedDNA has spent nearly two decades investing in deep genetics expertise and innovative technology to deliver the real-time insights and solutions our clients need to optimize clinical decisions, improve outcomes, and realize cost savings at scale. As the landscape of genomics continues to change, InformedDNA remains committed to building and implementing programs such as DNAimpact™ which integrates digital-first patient engagement tools to engage genomics and pharmacogenomics with proactive population care management in areas such as oncology, maternity, and polypharmacy to improve patient outcomes at scale. For more information, visit www.InformedDNA.com. Contact: Tim Walsh for InformedDNA +1 617.512.1641 timw@walshgroupmarketing.com

ST. PETERSBURG, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- InformedDNA®, a precision health company revolutionizing the application of genomic insights, today announced the acquisition of Coriell Life Sciences, a provider of pharmacogenomic services and clinical decision support. The addition of Coriell Life Science’s services to InformedDNA’s genetic test interpretation and counseling capabilities dramatically expands patient, provider and payor access to a broader range of genetic insights and enables more personalized, data-driven treatment and medication decisions for better outcomes and reduced healthcare costs. Philadelphia-based Coriell Life Sciences combines pharmacogenomics (the study of how genes affect an individual’s response to medication) and precision medicine (tailored diagnosis and treatment plans specific to each patient) to help large employers, health plans, payer organizations, health systems, and research institutions deliver paths to better health and more efficient care. The company’s offerings include both products and services. Corigen® is a population-scale medication risk management program that helps health plans, public and private employers, health systems, and pharmacy benefits managers ensure patients are getting the right medications for the best outcomes. Coriell Life Sciences also provides expert pharmacogenomic research analysis for laboratories. InformedDNA and Coriell Life Sciences have already started working together by integrating Coriell’s pharmacogenomic services into DNAimpact™, InformedDNA’s precision health platform. The combined offering identifies more targeted and effective therapies based on genomic profiles. It also combines interactive education and access to clinical experts to ensure patients and their providers are supported and guided to personalized health choices based on their genetics. Coriell Life Sciences CEO Scott Megill, who co-founded the company as a spin out from the Coriell Institute for Medical Research in 2013, will take on the new role of Chief Commercial Officer for InformedDNA. “The combination of our companies is a transformative step forward in the future of precision medicine,” said Megill. “By uniting our expertise in pharmacogenomics and clinical decision support with InformedDNA’s industry-leading genetic test interpretation and counseling services, we are creating an unparalleled resource for patients, providers, and health organizations. Already, through our new DNAimpact platform, we are expanding access to a broader range of genetic insights and helping individuals and healthcare teams make more personalized, data-driven decisions. This partnership ensures that more people than ever before can benefit from the life-changing potential of genetics.” “Pharmacogenomics is a critical aspect of personalized precision healthcare, and it presents an important opportunity to expand our ability to drive better patient outcomes,” said Dr. Surya Singh, CEO of InformedDNA. “Looking across the pharmacogenomics space, Coriell Life Sciences stands out for its extensive collaboration with leading laboratories that specialize in genetic and complex molecular testing. It also has experience working with a broad selection of employer plan sponsors. Scott and his team bring substantial expertise in the field and provide InformedDNA with an immediate presence in public employer plans currently underserved by precision medicine.”

DUBLIN--( BUSINESS WIRE )--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering. This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide. Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2030. Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases. Today, methods of commercializing induced pluripotent stem cells (iPSCs) include: Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease. Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models "in a dish". Drug Development and Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine. Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of iPSCs or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells. Tissue Engineering: iPSCs can be seeded onto scaffolds made from biocompatible materials. These scaffolds mimic the structure and properties of the target tissue and can provide a supportive environment for cell growth and differentiation. Organoid Production: iPS cells can be coaxed to self-organize into 3D structures called organoids, which mimic the structure and function of organs. Organoids can be used for studying organ development, modeling diseases, and testing drugs. Gene Editing: iPS cells can be genetically modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic changes. These edited iPS cells can then be differentiated into the desired cell type for transplantation or disease modeling. Research Tools: iPSCs and iPSC-derived cell types are being widely used within a diverse range of basic and applied research applications. Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors. Cultured Meat Production: iPSCs are being utilized in clean meat production by serving as the cellular foundation for the creation of lab-grown meat. 3D Bioprinting: iPSCs can be directed to differentiate into cell types of interest, such as skin, heart, or liver cells, which are then incorporated into bioinks. Wildlife Conservation and De-extinction Projects: iPSCs are being used in wildlife conservation and de-extinction projects. For example, Colossal Biosciences is using iPSC technology in an effort to achieve woolly mammoth de-extinction. Key Topics Covered: 1. REPORT OVERVIEW 2. INTRODUCTION 3. CURRENT STATUS OF IPSC INDUSTRY 3.1 Progress made in Autologous Cell Therapy using iPSCs 3.2 Allogeneic iPSC-based Cell Therapies 3.3 Share of iPSC-based Research within the Overall Stem Cell Industry 3.4 Major Focus Areas of iPSC Companies 3.5 Commercially Available iPSC-derived Cell Types 3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays 3.7 iPSC-derived Cell Types used in Clinical Trials 3.8 Currently Available iPSC Technologies Nucleofector Technology Opti-ox Technology MOGRIFY Technology Transcription Factor-based iPSC Differentiation Technology Flowfect Technology Technology for Mass Production of Platelets SynFire Technology 4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 5. RESEARCH PUBLICATIONS ON IPSCS 6. IPSC: PATENT LANDSCAPE ANALYSIS 6.1 iPSC Patent Applications by Jurisdiction 6.2 iPSC Patent Applicants 6.3 Inventors of iPSC Patents 6.4 iPSC Patent Owners 6.5 Legal Status of iPSC Patents 7. IPSC: CLINICAL TRIAL LANDSCAPE 7.1 Number of iPSC Clinical Trials 7.2 Recruitment Status of iPSC Clinical Trials 7.3 iPSC Clinical Trials Study Designs 7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials 7.5 iPSC-based Trials by Phase of Study 7.6 iPSC Clinical Trials by Funder Type 7.7 Geographic Distribution of iPSC-based Clinical Trials 7.8 Promising iPSC Product Candidates CYP-001, CYP-004 & CYP-006 from Cynata Therapeutics BioVAT-HF from Repairon GmbH HS-001 from Heartseed CNTY-101 from Century Therapeutics FT-576 & FT-819 from Fate Therapeutics RPE from National Eye Institute QN-019a from Qihan Biotech iPSC-CL from Heartworks, Inc. 7.9 Companies having Preclinical iPSC Assets Aspen Neuroscience Ryne Biotech Bluerock Therapeutics Vita Therapeutics Hopstem Biotechnology Res Nova Bio, Inc. Cytovia Therapeutics Hebecell Corporation Sana Biotechnology SCG Cell Therapy Pte Cytomed Shoreline Biosciences Neukio Biotherapeutics Exacis Biotherapeutics CellOrigin Biotech 8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR 8.1 Mergers and Acquisitions (M&A) Sector Century Therapeutics & Clade Therapeutics Evotech & Rigenerand Fujifilm Corporation & Atara Biotherapeutics Catalent & RheinCell Therapeutics Axol Biosciences & Censo Biotechnologies Bayer AG & Bluerock Therapeutics Pluriomix & Axiogenesis 8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector Shinobi Therapeutics & Panasonic SCG Cell Therapy and A*STAR Charles River Laboratories & Pluristyx, Inc. Pluristyx, Inc. & National Resilience, Inc. University of Texas & GeneCure Heartseed, Inc. & Undisclosed Biotech Bluerock Therapeutics & Bit.bio Applied Stem Cell, Inc. & CIRM Resolution Therapeutics & OmniaBio, Inc. REPROCELL, Inc. & CIRM REPROCELL, Inc. & BioBridge Global Elevate Bio & CIRM Evotec & Sernova Evotec & Almiral Quell Therapeutics & Cellistic MDimmune & YiPSCELL Edigene & Neukio Biotherapeutics Matricelf & Ramot Evotec & Boehringer Ingelheim Pluristyx, Pancella & Implant Therapeutics Century Therapeutics & Bristol Myers Squibb Fujifilm Cellular Dynamics & Pheno Vista Biosciences Metrion Biosciences & Bioqube Ventures Cytovia Therapeutics & Cellectis Exacis Biotherapeutics & CCRM Cynata Therapeutics & Fujifilm Corporation Bone Therapeutics & Implant Therapeutics REPROCELL & TEXCELL Jacobio & Herbecell NeuCyte & KIF1A.ORG Kite & Shoreline Biosciences Neuropath Therapeutics & Hopstem Biotechnology Allele Biotech & Cellatoz Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics Newcells & Takeda Biocentriq & Kytopen Fujifilm Cellular Dynamics & Sana Biotechnology Evotec & Medical Center Hamburg-Eppdorf (UKE) NeuCyte & Seaver Autism Center for Research and Treatment Cytovia Therapeutics & National Cancer Institute Mogrify & MRC Laboratory of Molecular Biology 8.3 Venture Capital Funding in iPSC Sector Asgard Therapeutics Kenai Therapeutics Pluristyx Fujifilm Cellular Dynamics Mogrify Ltd. Heartseed, Inc. Elevate Bio Aspen Neurosciences Axol Biosciences Thyas, Co. Ltd Synthego Cellino Biotech, Inc Curi Bio Ncardia Evotec SE bit.bio Clade Therapeutics Shoreline Biosciences Kytopen Cytovia Therapeutics & CytoLynx TreeFrog Therapeutics HebeCell Corporation Neukio Biotherapeutics Stemson Therapeutics Vita Therapeutics Century Therapeutics Heartseed Mogrify Metrion Biosciences Elevate Bio Vita Therapeutics 9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 9.1 OSKM Cocktail 9.2 Pluripotency-Associated Transcription Factors and their Functions 9.3 Delivery of Reprogramming Factors 9.3.1 Integrating Systems 9.3.2 Non-Integrative Delivery Systems 9.3.3 Comparison of Delivery Methods 9.4 Genome Editing Technologies in iPSC Generation 9.5 Available iPSC Lines and their applications 10. HUMAN IPSC BANKING 10.1 Major Biobanks Storing iPSCs & iPSC Lines 10.1.1 RIKEN 10.1.2 WiCell 10.1.3 Fujifilm Cellular Dynamics, Inc. 10.1.4 Sampled 10.1.5 Coriell Institute for Medical Research 10.1.6 European Bank for Induced Pluripotent Stem Cells (EBiSC) 10.2 Cell Sources for iPSC Banks 10.3 Reprogramming Methods in iPSC Banks 10.4 Ownership and Investments made in iPSC Banks 11. BIOMEDICAL APPLICATIONS OF IPSCs 11.1 iPSCs in Basic Research 11.2 Applications of iPSCs in Drug Discovery 11.3 Applications of iPSCs in Toxicology Studies 11.4 Applications of iPSCs in Disease Modeling 11.5 Applications of iPSCs in Cell-Based Therapies 11.6 Other Novel Applications of iPSCs 12. MARKET ANALYSIS 12.1 Global Market for iPSCs by Geography 12.2 Global Market for iPSCs by Technology 12.3 Global Market for iPSCs by Biomedical Application 12.4 Global Market for iPSCs by Derived Cell Type 12.5 Market Drivers 12.5.1 Current Drivers Impacting the iPSC Market Place 12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit https://www.researchandmarkets.com/r/pf57qx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.